Dipeptidyl Peptidase-4 as a New Target of Action for Type 2 Diabetes Mellitus: A Systematic Review

Cardiology Clinics

Volumn 26, Issue 4, 2008, Pages 639-648

  Wani, Javaid H ^a   John Kalarickal, Jennifer ^a   Fonseca, Vivian A ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Diabetes type 2; Dipeptidyl peptidase 4 inhibitor; DPP 4 inhibitors; Glycohemoglobin A1c; Incretins; Sitagliptin; Vildagliptin

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INCRETIN; INSULIN; METFORMIN; MK 04310; PIOGLITAZONE; PLACEBO; PRAMLINTIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ABDOMINAL PAIN; ADD ON THERAPY; BODY WEIGHT; CELL FUNCTION; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EDEMA; GASTROINTESTINAL SYMPTOM; GLUCAGON BLOOD LEVEL; GLUCAGON RELEASE; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET CELL; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; WEIGHT GAIN;

ADAMANTANE; ANIMALS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; NITRILES; PYRAZINES; PYRROLIDINES; TRIAZOLES;

EID: 53049091868     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2008.06.008     Document Type: Review

References (61)

1. Turner R.C., and Holman R.R. The UK prospective diabetes study. UK Prospective Diabetes Study Group. Ann Med 28 5 (1996) 439-444
2. Butler A.E., Janson J., Bonner-Weir S., et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52 1 (2003) 102-110
3. DeFronzo R.A., Bonadonna R.C., and Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 15 3 (1992) 318-368
4. Creutzfeldt W. The [pre-] history of the incretin concept. Regul Pept 128 2 (2005) 87-91
5. Perley M.J., and Kipnis D.M. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 46 12 (1967) 1954-1962
6. Verdich C., Flint A., Gutzwiller J.P., et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 86 9 (2001) 4382-4389
7. Willms B., Werner J., Holst J.J., et al. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 81 1 (1996) 327-332
8. Nauck M., Stockmann F., Ebert R., et al. Reduced incretin effect in type 2 (noninsulin-dependent) diabetes. Diabetologia 29 1 (1986) 46-52
9. Meier J.J., Hucking K., Holst J.J., et al. Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes 50 11 (2001) 2497-2504
10. Lynn F.C., Pamir N., Ng E.H., et al. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes 50 5 (2001) 1004-1011
11. Lynn F.C., Thompson S.A., Pospisilik J.A., et al. A novel pathway for regulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta-cells. FASEB J 17 1 (2003) 91-93
12. Zander M., Madsbad S., Deacon C.F., et al. The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes. Diabetologia 49 2 (2006) 369-374
13. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 60 11 (2006) 1454-1470
14. Tanaka T., Umeki K., Yamamoto I., et al. CD26 (dipeptidyl peptidase IV/DPP IV) as a novel molecular marker for differentiated thyroid carcinoma. Int J Cancer 64 5 (1995) 326-331
15. Cordero O.J., Ayude D., Nogueira M., et al. Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer. Br J Cancer 83 9 (2000) 1139-1146
16. Deacon C.F., Hughes T.E., and Holst J.J. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes 47 5 (1998) 764-769
17. Raz I., Chen Y., Wu M., et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 24 2 (2008) 537-550
18. Mu J., Woods J., Zhou Y.P., et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55 6 (2006) 1695-1704
19. Herman G.A., Stevens C., Van Dyck K., et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 78 6 (2005) 675-688
20. Bergman A.J., Stevens C., Zhou Y., et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 28 1 (2006) 55-72
21. Herman G.A., Bergman A., Stevens C., et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 91 11 (2006) 4612-4619
22. Herman G., Bergman A., and Wagner J.A. Sitagliptin, a DPP-4 inhibitor: an overview of the pharmacokinetic (PK) profile and the propensity for drug-drug interactions (DDI). [abstract]. Diabetologia 49 Suppl 1 (2006) 481-482
23. Herman G.A., Bergman A., Liu F., et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol 46 8 (2006) 876-886
24. Bergman A., Ebel D., Liu F., et al. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Biopharm Drug Dispos 28 6 (2007) 315-322
25. Hanefeld M., Herman G., Mickel C., et al. Effect of MK-0431, a dipeptidyl peptidase IV (DPP-4) inhibitor, on glycemic control after 12 weeks in patients with type 2 diabetes. Diabetologia 48 Suppl 1 (2005) 287-288
26. Raz I., Hanefeld M., Xu L., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 49 11 (2006) 2564-2571
27. Aschner P., Kipnes M.S., Lunceford J.K., et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29 12 (2006) 2632-2637
28. Scott R., Wu M., Sanchez M., et al. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 61 1 (2007) 171-180
29. Mannucci E., Ognibene A., Cremasco F., et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 24 3 (2001) 489-494
30. Goldstein B.J., Feinglos M.N., Lunceford J.K., et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 30 8 (2007) 1979-1987
31. Herman G.A., Bergman A., Yi B., et al. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when coadministered in patients with type 2 diabetes. Curr Med Res Opin 22 10 (2006) 1939-1947
32. Brazg R., Xu L., Dalla Man C., et al. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab 9 2 (2007) 186-193
33. Charbonnel B., Karasik A., Liu J., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 29 12 (2006) 2638-2643
34. Hermansen K., Kipnes M., Luo E., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 9 5 (2007) 733-745
35. Nauck M.A., Meininger G., Sheng D., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, noninferiority trial. Diabetes Obes Metab 9 2 (2007) 194-205
36. Rosenstock J., Brazg R., Andryuk P.J., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 28 10 (2006) 1556-1568
37. Mistry G.C., Bergman A.J., Luo W.L., et al. Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects. J Clin Pharmacol 47 2 (2007) 159-164
38. Barragan J.M., Rodriguez R.E., and Blazquez E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am J Physiol 266 3 Pt 1 (1994) E459-E466
39. Yamamoto H., Lee C.E., Marcus J.N., et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 110 1 (2002) 43-52
40. Toft-Nielsen M.B., Madsbad S., and Holst J.J. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22 7 (1999) 1137-1143
41. Mistry G.C., Maes A.L., Lasseter K.C., et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild-to-moderate hypertension. J Clin Pharmacol 48 5 (2008) 592-598
42. Ristic S., Byiers S., Foley J., et al. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 7 6 (2005) 692-698
43. Ahren B., Landin-Olsson M., Jansson P.A., et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89 5 (2004) 2078-2084
44. Pratley R.E., Jauffret-Kamel S., Galbreath E., et al. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 38 6 (2006) 423-428
45. Pi-Sunyer F.X., Schweizer A., Mills D., et al. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 76 1 (2007) 132-138
46. Dejager S., Razac S., Foley J.E., et al. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 39 3 (2007) 218-223
47. Balas B., Baig M.R., Watson C., et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 92 4 (2007) 1249-1255
48. Ahren B., Pacini G., Tura A., et al. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. Horm Metab Res 39 11 (2007) 826-829
49. Meier J.J., Gallwitz B., Salmen S., et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 88 6 (2003) 2719-2725
50. Vella A., Bock G., Giesler P.D., et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 56 5 (2007) 1475-1480
51. Mari A., Scherbaum W.A., Nilsson P.M., et al. Characterization of the influence of vildagliptin on model-assessed cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab 93 1 (2008) 103-109
52. Rosenstock J., Foley J.E., Rendell M., et al. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 31 1 (2008) 30-35
53. Pratley R.E., Rosenstock J., Pi-Sunyer F.X., et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care 30 12 (2007) 3017-3022
54. Schweizer A., Couturier A., Foley J.E., et al. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with type 2 diabetes. Diabet Med 24 9 (2007) 955-961
55. Rosenstock J., Baron M.A., Dejager S., et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 30 2 (2007) 217-223
56. Ahren B., Gomis R., Standl E., et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 27 12 (2004) 2874-2880
57. Bosi E., Camisasca R.P., Collober C., et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 30 4 (2007) 890-895
58. Garber A.J., Schweizer A., Baron M.A., et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 9 2 (2007) 166-174
59. Rosenstock J., Baron M.A., Camisasca R.P., et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 9 2 (2007) 175-185
60. Fonseca V., Schweizer A., Albrecht D., et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 50 6 (2007) 1148-1155
61. Nonaka K., Kakikawa T., Sato A., et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 79 2 (2008) 291-298